<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="http://www.fda.gov/oc/datacouncil/stylesheets/spl/spl.xsl" type="text/xsl"?><document xmlns="urn:hl7-org:v3" xmlns:voc="http://www.hl7.org/v3/voc" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.fda.gov/oc/datacouncil/schemas/spl/spl.xsd">
<id root="324a8674-c4a6-4afb-b504-aa2f67f5793e" />
<code code="34391-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="HUMAN PRESCRIPTION DRUG LABELING" />
<title ID="INV-acf4e3fe-7656-4671-9e18-10bbc1497454" mediaType="text/x-hl7-title+xml">Sodium Lactate Injection, USP (M/6 Sodium
        Lactate)<br />in VIAFLEX Plastic Container</title>
<effectiveTime value="20060526" />
<setId root="324a8674-c4a6-4afb-b504-aa2f67f5793e" />
<versionNumber value="1" />
<author>
<time />
<assignedEntity>
<representedOrganization>
<name>Baxter Healthcare Corporation</name>
</representedOrganization>
</assignedEntity>
</author>
<component>
<structuredBody>
<component>
<section>
<id root="39FC7C8A-FEB1-0EB1-7DF1-64B47D8C8CEB" />
<effectiveTime value="20060526" />
<subject>
<manufacturedProduct>
<manufacturedMedicine>
<code code="0338-0129" codeSystem="2.16.840.1.113883.6.69" />
<name>Sodium Lactate</name>
<formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION" />
<activeIngredient>
<quantity>
<numerator unit="g" value="1.87">
<translation code="C48155" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="GRAM" value="1.87" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="TU7HW0W0QT" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Sodium Lactate</name>
<activeMoiety>
<activeMoiety>
<code code="TU7HW0W0QT" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>sodium lactate</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<asEntityWithGeneric>
<genericMedicine>
<name>Sodium Lactate</name>
</genericMedicine>
</asEntityWithGeneric>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>Water</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<asContent>
<quantity>
<numerator unit="mL" value="500">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="500" />
</numerator>
<denominator value="1">
<translation codeSystem="2.16.840.1.113883.3.26.1.1" value="1" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code code="0338-0129-03" codeSystem="2.16.840.1.113883.6.69" />
<formCode code="C43167" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG" />
</containerPackagedMedicine>
</asContent>
<asContent>
<quantity>
<numerator unit="mL" value="1000">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="1000" />
</numerator>
<denominator value="1">
<translation codeSystem="2.16.840.1.113883.3.26.1.1" value="1" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code code="0338-0129-04" codeSystem="2.16.840.1.113883.6.69" />
<formCode code="C43167" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG" />
</containerPackagedMedicine>
</asContent>
</manufacturedMedicine>
<consumedIn>
<substanceAdministration>
<routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS" />
</substanceAdministration>
</consumedIn>
</manufacturedProduct>
</subject>
</section>
</component>
<component>
<section ID="INV-6ea97f66-9cb0-4acb-adbd-c413c06bcf24">
<id root="47F53551-2CEA-01A1-5108-10C971DED8A4" />
<code code="34089-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DESCRIPTION SECTION" />
<title ID="INV-e58b2fea-d11d-4a75-ac4d-ae0fbce38d33" mediaType="text/x-hl7-title+xml">DESCRIPTION</title>
<text ID="INV-dbb14f96-eb75-4cb7-b335-59977aadc450"><paragraph ID="INV-2297fae8-7111-4f4e-bf31-ad5a6fdd4923">Sodium Lactate
                            Injection, USP (M/6 Sodium Lactate) is a sterile, nonpyrogenic solution
                            for fluid and electrolyte replenishment and caloric supply in a single
                            dose container for intravenous administration. It contains no
                            antimicrobial agents. The pH may have been adjusted with lactic acid.
                            Composition, osmolarity, pH, ionic concentration and caloric content are
                            shown in Table 1.</paragraph><table><col align="left" width="125pt" />
<col align="left" width="75pt" />
<col align="left" width="100pt" />
<col align="left" width="100pt" />
<col align="left" width="100pt" />
<col align="left" width="100pt" />
<col align="left" width="100ptt" />
<col align="left" width="100pt" />
<tbody valign="top">
<tr valign="top"><td align="center" colspan="8" styleCode="Botrule                                         Lrule Rrule" valign="top"><content styleCode="bold">Table 1</content></td></tr>
<tr valign="top"><td align="center" rowspan="2" styleCode="Botrule Lrule Rrule" valign="middle">&#160;</td><td align="center" rowspan="2" styleCode="Botrule Rrule" valign="middle"> Size (mL) </td><td align="center" styleCode="Botrule Rrule" valign="middle">
                                        Composition (g/L) </td><td align="center" rowspan="2" styleCode="Botrule Rrule" valign="middle"><footnote ID="INV-180b6638-8eb5-4f58-b953-27baf4820dfc">Normal
                                            physiologic osmolarity range is approximately 280 to 310
                                            mOsmol/L. Administration of substantially hypertonic
                                            solutions (&#8805; 600 mOsmol/L) may cause vein
                                        damage.</footnote>Osmolarity (mOsmol/L) (calc)</td><td align="center" rowspan="2" styleCode="Botrule Rrule" valign="middle"> pH </td><td align="center" colspan="2" styleCode="Botrule Rrule" valign="middle"> Ionic Concentration (mEq/L) </td><td align="center" rowspan="2" styleCode="Botrule Rrule" valign="middle"> Caloric Content (kcal/L) </td></tr>
<tr valign="top"><td align="center" styleCode="Botrule Lrule                                         Rrule" valign="middle"> Sodium Lactate(C<sub>3</sub>H<sub>5</sub>NaO<sub>3</sub>) </td><td align="center" styleCode="Botrule Rrule" valign="middle">Sodium</td><td align="center" styleCode="Botrule Rrule" valign="middle">Lactate</td></tr>
<tr valign="top"><td align="left" rowspan="2" styleCode="Botrule Lrule Rrule" valign="middle">Sodium Lactate Injection,
                                        USP (M/6 Sodium Lactate) </td><td align="center" styleCode="Botrule Rrule" valign="middle"> 500 </td><td align="center" rowspan="2" styleCode="Botrule Rrule" valign="middle"> 18.7 </td><td align="center" rowspan="2" styleCode="Botrule Rrule" valign="middle"> 334 </td><td align="center" rowspan="2" styleCode="Botrule Rrule" valign="middle"> 6.5<br /> (6.0 to 7.3) </td><td align="center" rowspan="2" styleCode="Botrule Rrule" valign="middle"> 167 </td><td align="center" rowspan="2" styleCode="Botrule Rrule" valign="middle"> 167 </td><td align="center" rowspan="2" styleCode="Botrule Rrule" valign="middle"> 54 </td></tr>
<tr valign="top"><td align="center" styleCode="Botrule Lrule                                         Rrule" valign="middle">1000</td></tr>
</tbody>
</table><paragraph ID="INV-2941b7d4-4c17-405f-a690-c14b30b3485c">The VIAFLEX plastic
                            container is fabricated from a specially formulated polyvinyl chloride
                            (PL 146 Plastic). The amount of water that can permeate from inside the
                            container into the overwrap is insufficient to affect the solution
                            significantly. Solutions in contact with the plastic container can leach
                            out certain of its chemical components in very small amounts within the
                            expiration period, e.g., di-2-ethylhexyl phthalate (DEHP), up to 5 parts
                            per million. However, the safety of the plastic has been confirmed in
                            tests in animals according to USP biological tests for plastic
                            containers as well as by tissue culture toxicity studies.</paragraph></text>
<effectiveTime value="20060526" />
</section>
</component>
<component>
<section ID="INV-5b8193b7-10ed-4e3e-81fd-603b28056e2f">
<id root="3DED728E-E95B-C4EB-B90F-23032DDC1EC1" />
<code code="34090-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CLINICAL PHARMACOLOGY SECTION" />
<title ID="INV-d0ede16e-09fc-4789-967d-2efe000d921a" mediaType="text/x-hl7-title+xml">CLINICAL PHARMACOLOGY</title>
<text ID="INV-2b6198b9-ffa6-4d6f-87e6-668804a5313a"><paragraph ID="INV-9cf436ff-edd3-44ab-b1df-08c2c6d72ce3">Sodium Lactate
                            Injection, USP has value as a source of water, electrolytes, and
                            calories. It is capable of inducing diuresis depending on the clinical
                            condition of the patient. </paragraph><paragraph ID="INV-57989973-eea9-48ea-b25e-79fdb58ab2ec">Sodium Lactate
                            Injection, USP produces a metabolic alkalinizing effect. Lactate ions
                            are metabolized ultimately to carbon dioxide and water, which requires
                            the consumption of hydrogen cations.</paragraph></text>
<effectiveTime value="20060526" />
</section>
</component>
<component>
<section ID="INV-829344f1-4759-4016-a256-f0dd2b4a12d1">
<id root="6653C957-33C8-8F9C-8D2E-EC820F190972" />
<code code="34067-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="INDICATIONS AND USAGE SECTION" />
<title ID="INV-c70ca0fd-7487-489c-9563-1eaae8244c06" mediaType="text/x-hl7-title+xml">INDICATIONS AND USAGE</title>
<text ID="INV-385b17a7-40c3-4291-9f58-59008145f2a4"><paragraph ID="INV-6ea9db6f-0460-41ca-8d93-1663d55b04b5">Sodium Lactate
                            Injection, USP is indicated as a source of water, electrolytes, and
                            calories or as an alkalinizing agent.</paragraph></text>
<effectiveTime value="20060526" />
</section>
</component>
<component>
<section ID="INV-7197e1ca-a813-4cc3-84b5-bdc26f41b9f4">
<id root="EFC97976-702E-43DA-9700-7AE5358667DB" />
<code code="34070-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CONTRAINDICATIONS SECTION" />
<title ID="INV-67ad25fe-34f2-489d-8712-0478644bd2fc" mediaType="text/x-hl7-title+xml">CONTRAINDICATIONS</title>
<text ID="INV-aaf1ddce-251e-4c86-b236-0a107c0dc1a5"><paragraph ID="INV-1d979b67-a678-4bb2-8013-21258cf9704a">None             known</paragraph></text>
<effectiveTime value="20060526" />
</section>
</component>
<component>
<section ID="INV-ce43feac-0146-4dea-9a53-b2250a1b670f">
<id root="DE25AF7D-1A9E-BAA5-8084-2D7C84765274" />
<code code="34071-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="WARNINGS SECTION" />
<title ID="INV-35d562ab-e51f-4067-8df4-a6a070968df0" mediaType="text/x-hl7-title+xml">WARNINGS</title>
<text ID="INV-94b7111a-816c-4ca3-a432-3f6fc36d6d03"><paragraph ID="INV-33e11851-1990-488e-9037-5ebf28f75a41">Sodium Lactate
                            Injection, USP should be used with great care, if at all, in patients
                            with congestive heart failure, severe renal insufficiency, and in
                            clinical states in which there exists edema with sodium retention.</paragraph><paragraph ID="INV-b14b5b7a-7913-4396-bd52-08187e61c086">Sodium Lactate
                            Injection, USP should be used with great care in patients with metabolic
                            or respiratory alkalosis. The administration of lactate ions should be
                            done with great care in those conditions in which there is an increased
                            level or an impaired utilization of these ions, such as severe hepatic
                            insufficiency. </paragraph><paragraph ID="INV-b4cacc09-d109-48ae-b34c-ddd43c26a978">The intravenous
                            administration of these injections can cause fluid and/or solute
                            overloading resulting in dilution of serum electrolyte concentrations,
                            overhydration, congested states, or pulmonary edema. The risk of
                            dilutional states is inversely proportional to the electrolyte                     concentrations of the injection. The risk of solute overload causing
                            congested states with peripheral and pulmonary edema is directly
                            proportional to the electrolyte concentrations of the injection. </paragraph><paragraph ID="INV-7ee72ee8-ce07-4b95-b081-aeaaa4f9111b">Excessive
                            administration of Sodium Lactate Injection, USP may result in
                            significant hypokalemia. </paragraph><paragraph ID="INV-03376507-422a-4792-bbd5-50e10ca6db57">In patients with
                            diminished renal function, administration of Sodium Lactate Injection,
                            USP may result in sodium retention. </paragraph><paragraph ID="INV-01a105c4-fa49-4d16-9158-ce18de41741a">Sodium Lactate
                            Injection, USP is not for use in the treatment of lactic
                        acidosis.</paragraph></text>
<effectiveTime value="20060526" />
</section>
</component>
<component>
<section ID="INV-2e6cda67-7571-4574-a0b1-6b2a5038720b">
<id root="A2352E12-29CF-9E1C-F19B-64B56947663C" />
<code code="42232-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="PRECAUTIONS SECTION" />
<title ID="INV-7bcd28cf-b9b7-4985-a633-5ae037fcaa15" mediaType="text/x-hl7-title+xml">PRECAUTIONS</title>
<text ID="INV-d1c556a1-fbba-477d-ad36-606360cf300f"><paragraph ID="INV-92a0440f-df61-4292-a57d-bd5f762aa661">Clinical evaluation
                            and periodic laboratory determinations are necessary to monitor changes
                            in fluid balance, electrolyte concentrations, and acid base balance
                            during prolonged parenteral therapy or whenever the condition of the        patient warrants such evaluation. </paragraph><paragraph ID="INV-694cbdbe-9dd0-4f92-902e-f145da9a962f">Caution must be
                            exercised in the administration of these injections to patients
                            receiving corticosteroids or corticotropin.</paragraph></text>
<effectiveTime value="20060526" />
<component>
<section ID="INV-d062a252-ec7a-43ad-9d12-0c60d7155acc">
<id root="0BE2D7B1-C54E-8432-C4CA-1DFB62529978" />
<code code="42228-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="PREGNANCY" />
<title ID="INV-5ad1ada6-85bd-49c3-a302-00f5b4ea41ff" mediaType="text/x-hl7-title+xml">Pregnancy</title>
<effectiveTime value="20060526" />
<component>
<section ID="INV-f7714af6-9bc0-4e48-b5c1-b5486b769171">
<id root="E3375DFD-1FF6-3F80-D504-BB34291CC4A7" />
<code code="34077-8" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="TERATOGENIC EFFECTS SECTION" />
<title ID="INV-6efa8f12-e37d-4383-b1f8-9e1038b28e24" mediaType="text/x-hl7-title+xml">Teratogenic
                                        Effects</title>
<effectiveTime value="20060526" />
<component>
<section>
<id root="F376D06C-1C8C-73ED-79CE-5B6FD9F6380C" />
<title ID="INV-671bd5d8-adf3-450e-a98c-d38b46905b4b" mediaType="text/x-hl7-title+xml">Pregnancy Category C</title>
<text ID="INV-d37652a9-b375-4fb3-8a5b-0b336569cffc"><paragraph ID="INV-4e75898b-896b-4f98-949b-9f4fa6be56d6">Animal reproduction studies have not been
                                                  conducted with Sodium Lactate Injection, USP. It
                                                  is also not known whether Sodium Lactate
                                                  Injection, USP can cause fetal harm when
                                                  administered to a pregnant woman or can affect
                                                  reproduction capacity. Sodium Lactate Injection,
                                                  USP should be given to a pregnant woman only if
                                                  clearly needed.</paragraph></text>
<effectiveTime value="20060526" />
</section>
</component>
</section>
</component>
</section>
</component>
<component>
<section ID="INV-61c20fa7-7132-4d62-a076-4eae08ad7de6">
<id root="4ECBBFD7-C43A-A5DC-6873-D2C01F244660" />
<code code="34081-0" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="PEDIATRIC USE SECTION" />
<title ID="INV-93b317b8-369f-4ec1-96c7-92397206f316" mediaType="text/x-hl7-title+xml">Pediatric Use</title>
<text ID="INV-0657d442-6636-4aa5-a456-776d35e3475f"><paragraph ID="INV-a06f6491-f038-41cc-bd9f-69e54b9fa1dc">Safety and
                                    effectiveness of Sodium Lactate Injection, USP in pediatric
                                    patients have not been established by adequate and well
                                    controlled trials, however, the use of sodium lactate solutions
                                    in the pediatric population is referenced in the medical
                                    literature. The warnings, precautions and adverse reactions
                                    identified in the label copy should be observed in the pediatric
                                    population.</paragraph></text>
<effectiveTime value="20060526" />
</section>
</component>
<component>
<section ID="INV-03ce3937-2c5a-4594-9ba1-449b4330ece0">
<id root="E9431FC0-5296-1820-5764-14F8BEEFD9A4" />
<code code="34083-6" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CARCINOGENESIS AND MUTAGENESIS                                 AND IMPAIRMENT OF FERTILITY SECTION" />
<title ID="INV-3c77f1f3-2a66-4d4d-a1cb-7f21d96b48b5" mediaType="text/x-hl7-title+xml">Carcinogenesis,
                                Mutagenesis, Impairment of Fertility</title>
<text ID="INV-cd8e92ce-0de2-406b-889c-4625093c37db"><paragraph ID="INV-397ac290-52ca-4641-8480-2b30c3fefb08">Studies
                                    with Sodium Lactate Injection, USP have not been performed to
                                    evaluate carcinogenic potential, mutagenic potential, or effects
                                    on fertility.</paragraph></text>
<effectiveTime value="20060526" />
</section>
</component>
<component>
<section ID="INV-f2443e5d-3243-40b2-beb7-51670b62555b">
<id root="BFC70C36-E5E6-BBD5-6DDF-88161EB8AB5F" />
<code code="34080-2" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="NURSING MOTHERS SECTION" />
<title ID="INV-2122becc-ba1e-4f8a-8fa5-67c6c8e7b9a7" mediaType="text/x-hl7-title+xml">Nursing Mothers</title>
<text ID="INV-da7c5b75-7264-4b9f-9506-78f919f7ba2d"><paragraph ID="INV-ac9f94e5-f4ff-4d35-a180-5e5ee6164d1a">It is not
                                    known whether this drug is excreted in human milk. Because many
                                    drugs are excreted in human milk, caution should be exercised
                                    when Sodium Lactate Injection, USP is administered to a nursing
                                    mother.</paragraph></text>
<effectiveTime value="20060526" />
</section>
</component>
<component>
<section ID="INV-bac7b109-d549-4de4-8a20-78c87c98429c">
<id root="2A70F656-9554-8ED7-9405-DF8E6C0CC8C6" />
<code code="34082-8" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="GERIATRIC USE SECTION" />
<title ID="INV-17ebfe31-5721-4fa1-8777-3e86b976e767" mediaType="text/x-hl7-title+xml">Geriatric Use</title>
<text ID="INV-ae5473c2-5899-4fbb-9e13-a3cab9001c68"><paragraph ID="INV-5b9c58ef-356f-465f-b941-40ee5521aa9a">Clinical
                                    studies of Sodium Lactate Injection, USP did not include
                                    sufficient numbers of subjects aged 65 and over to determine
                                    whether they respond differently from younger subjects. Other
                                    reported clinical experience has not identified differences in
                                    responses between the elderly and younger patients. In general,
                                    dose selection for an elderly patient should be cautious,
                                    usually starting at the low end of the dosing range, reflecting
                                    the greater frequency of decreased hepatic, renal, or cardiac
                                    function, and of concomitant disease or drug therapy. </paragraph><paragraph ID="INV-ab1af7ee-5704-4852-9489-5bb1ad727f26">Do not
                                    administer unless solution is clear and seal is
                                intact.</paragraph></text>
<effectiveTime value="20060526" />
</section>
</component>
</section>
</component>
<component>
<section ID="INV-bbe5f203-0a89-4a05-94c0-08361baa25a5">
<id root="889254ED-7EF8-772B-45B4-F38F448CBE27" />
<code code="34084-4" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="ADVERSE REACTIONS SECTION" />
<title ID="INV-1ed92089-a2a0-4577-8b03-3e29e105316c" mediaType="text/x-hl7-title+xml">ADVERSE REACTIONS</title>
<text ID="INV-8c1aeb45-0814-4af3-803c-7bfe54cb4a39"><paragraph ID="INV-fc748510-a020-4ee7-92e6-2c4003dd0d3a">Reactions which may
                            occur because of the solution or the technique of administration include
                            febrile response, infection at the site of injection, venous thrombosis
                            or phlebitis extending from the site of injection, extravasation and
                            hypervolemia. </paragraph><paragraph ID="INV-a4d3cb10-8c3d-4c2c-850d-919d99c07451">If an adverse
                            reaction does occur, discontinue the infusion, evaluate the patient,
                            institute appropriate therapeutic countermeasures, and save the
                            remainder of the fluid for examination if deemed necessary.</paragraph></text>
<effectiveTime value="20060526" />
</section>
</component>
<component>
<section ID="INV-4ffcc598-9bce-472a-b79b-81fb2eafb1e5">
<id root="BA5810A8-B455-1B50-BA8A-482681F0DE07" />
<code code="34068-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DOSAGE AND ADMINISTRATION SECTION" />
<title ID="INV-38280042-e01a-46a5-8d3c-3747c0ddb5f7" mediaType="text/x-hl7-title+xml">DOSAGE AND ADMINISTRATION</title>
<text ID="INV-f2f59fe5-a3f8-45c9-a003-61338680e770"><paragraph ID="INV-ff5b1eb6-e5a9-425f-a4f0-7d399a5a2ddb">As directed by a
                            physician. Dosage is dependent upon the age, weight and clinical
                            condition of the patient as well as laboratory determinations. </paragraph><paragraph ID="INV-e4233d3c-aad5-4c2f-8b68-5357cdcd2443">Parenteral drug
                            products should be inspected visually for particulate matter and
                            discoloration prior to administration whenever solution and container
                            permit. Use of a final filter is recommended during administration of
                            all parenteral solutions, where possible. </paragraph><paragraph ID="INV-37a37f1e-9b2b-4843-9dd1-b0bbc8ef984d">All injections in
                            VIAFLEX plastic containers are intended for intravenous administration
                            using sterile equipment. </paragraph><paragraph ID="INV-e742a7cd-a238-4594-b4a1-bbea5c8d758d">Additives may be
                            incompatible. Complete information is not available. Those additives
                            known to be incompatible should not be used. Consult with pharmacist, if
                            available. If, in the informed judgment of the physician, it is deemed
                            advisable to introduce additives, use aseptic technique. Mix thoroughly
                            when additives have been introduced. Do not store solutions containing
                            additives.</paragraph></text>
<effectiveTime value="20060526" />
</section>
</component>
<component>
<section ID="INV-087695a4-eb7a-48dc-b0f1-a1fd0e705845">
<id root="AE2DDCA0-561E-7D35-EAEA-7090BA457729" />
<code code="34069-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="HOW SUPPLIED SECTION" />
<title ID="INV-6d33e27b-98a5-4639-9e4d-89ed60e1033d" mediaType="text/x-hl7-title+xml">HOW SUPPLIED</title>
<text ID="INV-5b55ad6c-ae29-45de-9cb2-7e53b900d25b"><paragraph ID="INV-12ebbf36-51d0-4dfb-a073-d5f59155e36f">Sodium Lactate
                            Injection, USP (M/6 Sodium Lactate) in VIAFLEX plastic container is
                            available as follows:</paragraph><table frame="void"><col align="left" width="125pt" />
<col align="left" width="125pt" />
<col align="left" width="125pt" />
<tbody valign="top">
<tr valign="top"><td align="left" valign="middle"> Code </td><td align="left" valign="middle"> Size
                                        (mL) </td><td align="left" valign="middle"> NDC </td></tr>
<tr valign="top"><td align="left" valign="middle">
                                        2B1803 </td><td align="left" valign="middle"> 500 </td><td align="left" valign="middle">
                                        0338-0129-03 </td></tr>
<tr valign="top"><td align="left" valign="middle"> 2B1804 </td><td align="left" valign="middle"> 1000 </td><td align="left" valign="middle"> 0338-0129-04 </td></tr>
</tbody>
</table><paragraph ID="INV-0ebf7efe-6ca1-41a1-b42b-b8f487e35187">Exposure of
                            pharmaceutical products to heat should be minimized. Avoid excessive
                            heat. It is recommended the product be stored at room temperature
                            (25&#186;C); brief exposure up to 40&#186;C does not adversely affect the
                        product.</paragraph></text>
<effectiveTime value="20060526" />
</section>
</component>
<component>
<section ID="INV-c0921c48-c0dc-4244-818c-4c713d0cd03f">
<id root="0CF44EB3-3480-238E-EDF5-E97BA766C0D5" />
<title ID="INV-ad80994b-c9c4-4631-81a0-96a5de428ed1" mediaType="text/x-hl7-title+xml">DIRECTIONS FOR USE OF
                        VIAFLEX PLASTIC CONTAINER</title>
<text ID="INV-e55e0101-c87c-40a0-8b93-39c38e7b9b94"><paragraph ID="INV-089b51e3-5b2a-444c-8573-3f62890730d4"><content styleCode="bold">Warning:</content> Do not use plastic containers in
                            series connections. Such use could result in air embolism due to
                            residual air being drawn from the primary container before
                            administration of the fluid from the secondary container is
                        completed.</paragraph></text>
<effectiveTime value="20060526" />
<component>
<section ID="INV-18d1520c-ce38-47d1-9d91-21e2a7d1e923">
<id root="5F25A5A1-BE00-F115-84B2-586DC4CEDB6C" />
<title ID="INV-ba138587-fe11-4aa0-8537-6485cd6e849a" mediaType="text/x-hl7-title+xml">To Open </title>
<text ID="INV-6d5f8d5b-9d59-4c6f-ba8b-4ef664b5d642"><paragraph ID="INV-e3db19a3-cd32-4b85-8445-e0453a23468a">Tear
                                    overwrap down side at slit and remove solution container. Some
                                    opacity of the plastic due to moisture absorption during the
                                    sterilization process may be observed. This is normal and does
                                    not affect the solution quality or safety. The opacity will
                                    diminish gradually. Check for minute leaks by squeezing inner
                                    bag firmly. If leaks are found, discard solution as sterility
                                    may be impaired. If supplemental medication is desired, follow
                                    directions below.</paragraph></text>
<effectiveTime value="20060526" />
</section>
</component>
<component>
<section ID="INV-2b094c69-5f12-4761-bb60-4cacf8dd8d9f">
<id root="AC7F5642-CF05-F46B-4261-375D491189F3" />
<title ID="INV-b34b9449-3954-4f4f-993e-e559a19b00e9" mediaType="text/x-hl7-title+xml">Preparation for
                                Administration </title>
<text ID="INV-4065c920-da73-433a-b9a0-6a842597bc53"><list listType="ordered" styleCode="Arabic"><item>Suspend container from eyelet support. </item><item>Remove plastic protector from outlet port at bottom of
                                        container. </item><item>Attach administration set. Refer to complete directions               accompanying set.</item></list></text>
<effectiveTime value="20060526" />
</section>
</component>
<component>
<section ID="INV-b740568a-70de-43ec-888f-f595b4e6d857">
<id root="E0D6B39D-F4C3-9A01-8E32-C1D031523F14" />
<title ID="INV-b184a94c-8bcf-4cd5-93b6-ac0ee80fb130" mediaType="text/x-hl7-title+xml">To Add Medication</title>
<text ID="INV-f2cf2334-1151-4af5-929d-a80290250013"><paragraph ID="INV-2a858230-d007-4775-97a0-b659bcee6e68"><content styleCode="bold">Warning:</content> Additives may be
                                    incompatible.</paragraph></text>
<effectiveTime value="20060526" />
<component>
<section ID="INV-cee203c1-8abb-4a7f-a71f-884ec6a451a5">
<id root="7891400B-506A-6A94-78BD-CE2BDA6F9A1B" />
<title ID="INV-0bcb26b7-a049-49d3-abda-d459ae8c94e7" mediaType="text/x-hl7-title+xml">To add
                                        medication before solution administration </title>
<text ID="INV-057b7330-14d5-4877-8750-02389fffde2e"><list listType="ordered" styleCode="Arabic"><item>Prepare medication site. </item><item>Using syringe with 19 to 22 gauge needle, puncture
                                                resealable medication port and inject. </item><item>Mix solution and medication thoroughly. For high
                                                density medication such as potassium chloride,
                                                squeeze ports while ports are upright and mix                    thoroughly.</item></list></text>
<effectiveTime value="20060526" />
</section>
</component>
<component>
<section ID="INV-68b80d21-8820-431b-8239-de9b39b63887">
<id root="5A1D8DE4-7C0E-16D6-BAA7-2BACBC282E04" />
<title ID="INV-0dba7487-b269-4d49-b28c-9d4751cda5e1" mediaType="text/x-hl7-title+xml">To add
                                        medication during solution administration </title>
<text ID="INV-ddcb23df-f558-42a6-a20a-0aa0bdd661c5"><list listType="ordered" styleCode="Arabic"><item>Close clamp on the set. </item><item>Prepare medication site. </item><item>Using syringe with 19 to 22 gauge needle, puncture
                                                resealable medication port and inject. </item><item>Remove container from IV pole and/or turn to an
                                                upright position. </item><item>Evacuate both ports by squeezing them while
                                                container is in the upright position. </item><item>Mix solution and medication thoroughly. </item><item>Return container to in use position and continue
                                                administration.</item></list><paragraph ID="INV-87490005-2d00-48dc-9ca8-d9930052155f" /><paragraph ID="INV-4b6ffa8a-00b4-4541-a3bb-72dcb51bd0cc"><content styleCode="bold">Baxter Healthcare
                                            Corporation</content></paragraph><paragraph ID="INV-1b0af95a-bdf5-41bf-82ff-6abfc4408670">Deerfield, IL 60015 USA</paragraph><paragraph ID="INV-3ab73aea-a936-4569-8932-f617d2127ca4">Printed in USA</paragraph><paragraph ID="INV-454ba6c9-39dd-45a7-9a6c-1fdaa01d106f">*Bar Code Position Only</paragraph><paragraph ID="INV-6aa50070-9eb5-44bf-a40c-9f136044bb74">071939581</paragraph><paragraph ID="INV-def89011-039d-4325-9792-256d9a244eb0">&#169;Copyright 1982, 1983, 1989, 1995, Baxter Healthcare       Corporation. </paragraph><paragraph ID="INV-0456bd1f-0406-4232-839c-f6b3ff66d105">All
                                            rights reserved.</paragraph><paragraph ID="INV-e08c1ef6-45bc-4f1e-b799-02e313cad99d"><content styleCode="bold">7-19-39-581</content></paragraph><paragraph ID="INV-b704dbfd-0f5d-4f2c-83d8-dc3e8c09732c">BAXTER, VIAFLEX, and PL 146 are trademarks of </paragraph><paragraph ID="INV-0b5bf048-d877-4376-850c-8a6add2cdcd8">Baxter International Inc.</paragraph></text>
<effectiveTime value="20060526" />
</section>
</component>
</section>
</component>
</section>
</component>
</structuredBody>
</component>
</document>
